Konakion

Phytomenadione, the active ingredient in Konakion, is a Vitamin K presented as a vitamin K preparation for intramuscular, intravenous, and oral use. It is employed to prevent and treat vitamin K deficiency bleeding, to provide prophylaxis of hemorrhage in newborns, and to reverse the effects of anticoagulant therapy such as warfarin.

GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance, and timely delivery.

Konakion (phytomenadione) is used to address disorders of the coagulation cascade related to vitamin K deficiency. - Vitamin K deficiency bleeding: prevents and treats bleeding caused by insufficient vitamin K. - Newborn hemorrhage prophylaxis: reduces risk of hemorrhagic disease of the newborn. - Anticoagulant reversal: restores clotting factor activity after warfarin or other vitamin K antagonist therapy.

Phytomenadione may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: discomfort or soreness at the site of intramuscular or intravenous administration. - Nausea: mild gastrointestinal upset following oral intake. - Headache: transient headache reported in some patients. - Fever: low‑grade pyrexia occurring after injection.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hemolysis: rare destruction of red blood cells. - Thrombosis: unexpected clot formation in veins or arteries. - Hyperbilirubinemia: elevated bilirubin levels, particularly in neonates.

When using Konakion, several precautions should be observed to ensure safety and efficacy. - Contraindication: do not use in patients with known hypersensitivity to phytomenadione or any excipients. - Bleeding disorders: monitor coagulation parameters in patients with existing coagulopathies. - Liver disease: assess hepatic function as synthesis of clotting factors may be impaired. - Neonates: adjust dosing and monitor for hyperbilirubinemia in newborns. - Drug interactions: review concurrent anticoagulant or vitamin K antagonist therapy. - Store at room temperature: keep in original container, protect from moisture and light.

Phytomenadione can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Warfarin: may reduce anticoagulant effect, requiring dose adjustment and INR monitoring. - Broad‑spectrum antibiotics (e.g., cephalosporins): can impair vitamin K synthesis, potentially altering response.

Moderate Interactions (Monitor Closely): - Rifampin: may increase metabolism of vitamin K, decreasing its effectiveness. - Cholestyramine or other bile‑acid sequestrants: can reduce absorption of oral phytomenadione. - Heparin: concurrent use may increase bleeding risk; monitor coagulation status.